DRUG EVALUATION Methylnaltrexone for the management of unwanted peripheral opioid effects Peter Holzer For many a patient suffering from moderate to severe pain, opioid analgesics offer the Medical University of Graz, Research Unit of anxiously sought-after relief, but at a high price. While the pain is wearing off, distressful Translational constipation, abdominal discomfort, nausea and urinary retention ensue. These unwanted Neurogastroenterology, effects have been difficult to deal with, and the laxatives that are usually prescribed Institute of Experimental and Clinical Pharmacology, ameliorate constipation in no more than 50% of the patients receiving opiates. A new Universitätsplatz 4, treatment concept emerged from the development of opioid receptor antagonists with a A-8010 Graz, Austria peripherally restricted site of action. One of these treatments is methylnaltrexone, which Tel.: +43 316 380 4500 Fax: +43 316 380 9645 clinical trials have shown to be of benefit in opioid-induced constipation, postoperative
[email protected] ileus and urinary retention, while analgesia remains unabated. The drug is well tolerated and holds great promise in freeing opioid therapy of some of its most-feared adverse aspects. In 2008, methylnaltrexone (RelistorTM) was approved in the USA, Canada and Europe for the treatment of opioid-induced constipation in patients with advanced illness. Opioids denominate exogenous and endogenous the bowel, anorexia, nausea and vomiting, as well compounds that activate the principal µ-, κ- and as interference with oral drug administration and δ-opioid receptors. The term opioid has been absorption [1,2]. The symptoms associated with derived from opium, which refers to the dried OBD can profoundly impair the quality of life, latex collected from the unripe seed capsules of and in some patients can be so severe that they Papaver somniferum.